Below are the most recent publications written about "Induction Chemotherapy" by people in Profiles.
-
Davitt M, Offenbacher R, Lee MA, Loeb DM, Manwani D, Mitchell W, Weiser DA. Atypical hemolytic uremic syndrome during induction chemotherapy in neuroblastoma, a rare phenomenon or common congenital predisposition? Pediatr Blood Cancer. 2024 09; 71(9):e31175.
-
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022 Feb 01; 327(5):464-477.
-
Acuna-Villaorduna A, Shankar V, Wysota M, Jirgal A, Kabarriti R, Bellemare S, Goldman I, Kaubisch A, Aparo S, Goel S, Chuy J. Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma. Cancer Control. 2022 Jan-Dec; 29:10732748221134411.
-
Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Schmucker AM, Leiby BE, Wilde L. Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2022 03; 22(3):e206-e212.
-
Jeurkar C, Wilde L, Leiby BE, Banks J, Kasner M, Keiffer G, Filicko-O'Hara J, Palmisiano N. Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival. Leuk Res. 2021 04; 103:106533.
-
Tuazon SA, Holmberg LA, Nadeem O, Richardson PG. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021 02 04; 11(2):23.
-
Ahn PH, Machtay M, Anne PR, Cognetti D, Keane WM, Wuthrick E, Dicker AP, Axelrod RS. Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer. Am J Clin Oncol. 2018 05; 41(5):441-446.
-
Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK, Libby EN. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Amyloid. 2016 Dec; 23(4):254-259.
-
Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016 05 10; 34(14):1620-5.